Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome

NCT00346814 is registered in ClinicalTrials.gov with Asociación para Evitar la Ceguera en México as lead sponsor.

NCT NCT00346814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00346814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome
Lead sponsor
Asociación para Evitar la Ceguera en México
Phase
Phase 2/3
Overall status
Unknown status
Start date
July 31, 2007
Completion date
November 30, 2024
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

retinopathy of prematurity